Antibody-Drug Conjugates for Cancer Therapy.

Hafeez U, Parakh S, Gan HK, Scott AM. · 2020

Read Antibody-Drug Conjugates for Cancer Therapy. by Hafeez U, Parakh S, Gan HK, Scott AM. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7587605.txt.

Introduction

Hafeez, Parakh, Gan and Scott review antibody-drug conjugates for cancer therapy. These drugs pair an antibody with a toxic payload. The antibody seeks antigens on cancer cells.

That targeting spares much healthy tissue from harm. It can widen the usable treatment window for drugs. Nine such drugs had FDA approval at review time. More than 80 were in clinical development worldwide. The review covers design of each ADC component. Biology and chemistry of linkers and payloads are explained. Clinical results for approved drugs are summarized. Resistance pathways and future designs are also covered. Molecular imaging roles in drug work are discussed.

Catalog record

CREATORHafeez U, Parakh S, Gan HK, Scott AM.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE106 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7587605

Browse the full library · About the Tower of Babel